Deep Liver Phenotyping and Immunology Study (DELPHI)
Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two most common causes of primary liver cancer and HCC is the second highest cause of cancer death worldwide. It is known that most of these cancers occur in patients who already have a liver condition. Despite close monitoring of many patients who have liver disease with regular ultrasound scans, HCC and cholangiocarcinoma are often discovered at a late stage. This is because they rarely cause symptoms until they have reached an advanced stage. Early identification of these cancers would enable more patients to have curative treatments such as surgery or liver transplantation.
The investigators want to collect blood and urine samples as well as small samples of cells directly from the liver. In some cases this will be done using a technique called liver fine needle aspiration. This technique is low risk and has been successfully used in other studies. The investigators will compare samples from patients with cancer to those of patients with other diseases of the liver who are at risk of developing cancer in the future.
The investigators aim to detect changes in the liver, blood, urine and/or bile of patients who have liver conditions that could tell us their risk of a future cancer. These changes could be in the types of white blood cells found within the liver, or, they may be in products secreted by liver cells. In the latter case the liver cells may release small pieces of their DNA that could be detected in the blood. When liver cells are dysfunctional, they may also change the types of metabolic products that they produce, and the investigators may be able to detect these changes in the urine or bile.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The purpose of this study is to perform a characterisation of the cancer predisposing 'field effect' that is associated with hepatic & hepato-biliary malignancy, and, to identify minimally invasive biomarkers that may detect this field effect. This will be achieved through collection of patient samples (Tissue/Blood/Urine/Bile). Comparisons will then be made between patients with hepatic & hepatobiliary cancer and patients with chronic liver disease and also longitudinally in individual patients who either develop or are cured of hepatic & hepato-biliary malignancy during the study. The investigators hope to exploit this knowledge to develop novel biomarker candidates that may ultimately form inputs to a multi-parametric early cancer detection model. The study aims are:
- Develop a cohort of patients with HCC, cholangiocarcinoma or liver metastases and a cohort of chronic liver disease patients representing all the commonly encountered aetiologies (viral, metabolic, autoimmune and alcohol related liver disease).
- Collect samples from directly within the non-cancerous liver (FNA liver/biopsy/ablation/resection specimens), blood and urine in addition tumour tissue (resection/biopsy/ablation), bile and bile duct brushings.
- Flow cytometric & molecular biologic analysis of tissue and peripheral blood and bile.
- Transcriptomic analysis of cell populations in liver and blood.
- Genetic & molecular biologic analysis of hepatic and immune cells and secreted products.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Rory J Peters
- Numéro de téléphone: +441865220077
- E-mail: Rory.peters@ndm.ox.ac.uk
Lieux d'étude
-
-
Oxfordshire
-
Oxford, Oxfordshire, Royaume-Uni, OX3 9DU
- Recrutement
- John Radcliffe Hospital
-
Contact:
- Rory J Peters
- Numéro de téléphone: +441865220077
- E-mail: Rory.peters@ndm.ox.ac.uk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years to 75 years.
Malignancy Cohort: extra inclusion criteria - Diagnosed with a malignancy or with clinical suspicion of a malignancy affecting the Liver or Biliary Tree.
Control cohort: extra inclusion criteria
- Patients with confirmed chronic non-malignant hepatobiliary disease.
Additional Inclusion Criteria for Patients Undergoing optional Liver FNA
- Willing to undergo ultrasound guided liver FNA (unless specific contra-indications to the procedure apply).
- Has undergone appropriate clinical imaging of the upper abdomen (US/CT/MRI) within the last 12 months.
- Full blood count (FBC) and coagulation profile (Coag) checked within 30 days prior to FNA procedure (Baseline Visit).
Exclusion Criteria:
- Unable to consent.
- Pregnancy.
- Any concern by the investigator regarding the safe participation of the patient in the study; or investigator's consideration, for any other reason, that a patient is inappropriate for participation in the study.
Additional Exclusion Criteria for Patients Undergoing optional Liver FNA (These criteria will exclude a patient from having FNA as part of the study)
- Significant comorbid medical condition(s) which may in the opinion of the investigator increase the risk of an FNA Liver.
- Coagulopathy - International Normalized Ratio (INR) >1.3, Prothrombin Time (PT) >16 seconds, Platelet count <100 x 10^3/L.
- Known bleeding disorder (e.g. Haemophilia).
- Current use of an oral/injectable anticoagulant medication.
- Current use of an oral antiplatelet agent.
- The presence of ascites.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Malignancy Cohort
Patients with hepatic or hepatobiliary malignancy at enrolment
|
|
Control Cohort
Patients with chronic liver disease but no hepatic or hepatobiliary malignancy at enrolment
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Measurement of intra-hepatic and peripheral blood immune cell numbers in Malignancy Cohort and Control Cohort patients.
Délai: At study enrolment
|
Proportion of immune cell populations relative to total immune cell count measured by single cell RNA sequencing.
|
At study enrolment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Measurement of liver cancer occurrence and all-cause mortality.
Délai: 15 years
|
Measurement of absolute numbers of liver cancers and deaths in study patients
|
15 years
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Measure safety of fine needle aspiration in cirrhosis
Délai: 5 years
|
Measurement of absolute numbers of adverse events related to liver fine needle aspiration in study patients with cirrhosis.
|
5 years
|
|
Measure tolerability of liver fine needle aspiration
Délai: 5 years
|
Measure post procedure analgesia dose and duration in patients undergoing liver fine needle aspiration as a study procedure
|
5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Rory J Peters, University of Oxford
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 264839
- C2195/A27431 (Autre subvention/numéro de financement: Cancer Research UK)
- CA30358/A29725 (Autre subvention/numéro de financement: Cancer Research UK)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .